Why Olaparib Timing Matters in BRCA-Mutated Early-Stage Breast Cancer

Women whose BRCA1 or BRCA2 gene carries an inherited mutation face a higher risk of aggressive breast cancers, particularly triple-negative breast cancer (TNBC). Although targeted agents have been developed alongside conventional chemotherapy, improving response and prolonging survival remain important needs. PARP inhibitors, particularly olaparib, target DNA repair and stand out as promising treatments.

With results published on May 13, 2025, in Nature Communications , the PARTNER study took an innovative approach by examining how the timing of neoadjuvant (preoperative) olaparib given with chemotherapy affects treatment success.

PARTNER Study Overview: What Was Investigated?

PARTNER is a randomized phase II/III clinical trial conducted at 23 UK centers in women with BRCA1/2-mutated early-stage breast cancer.

The aim was to determine when adding olaparib to chemotherapy would be most effective and safe.

Patient Groups:

• Investigational arm (gap schedule): Olaparib started 48 hours after chemotherapy.

• Control arm: Standard chemotherapy alone.

• Discontinued arm (non-gap schedule): Olaparib started 2 days before chemotherapy.

Pathologic Complete Response Rate

The two groups did not differ significantly in the primary endpoint, pathologic complete response (pCR):

• Investigational arm: 64.1% (25/39)

• Control arm: 69.8% (30/43)

• p-value = 0.586

This timing of olaparib therefore did not directly improve complete cancer eradication.

But the Survival Findings Were Much More Striking!

Despite similar pCR rates, the olaparib group showed clear survival advantages:

At 36 Months of Follow-Up:

• Event-free survival (EFS):

  • Investigational arm: 96.4%

  • Control arm: 80.1%

  • p = 0.04

• Overall survival (OS):

  • Investigational arm: 100%

  • Control arm: 88.2%

  • p = 0.04

• Breast cancer-specific survival:

  • Investigational arm: 100%

  • Control arm: 88.2%

  • p = 0.04

These results show that the gap schedule, starting olaparib 48 hours after chemotherapy, had a strong effect on prolonging survival.

Why Timing Matters: What Difference Does Waiting 48 Hours Make?

Preclinical experiments showed that olaparib administered immediately after chemotherapy increased bone marrow toxicity, whereas a 48-hour delay reduced toxicity while maintaining antitumor activity. When these findings were translated to the clinic:

• Starting olaparib before chemotherapy (the discontinued arm): survival decreases

• Starting olaparib after chemotherapy (the investigational arm): survival increases

Safety Profile and Adverse Reactions

• The rate of severe (grade ≥3) adverse reactions was 76.9% in the investigational arm and 60.0% in the control arm.

• However, treatment-related discontinuation rates were similar: 7.7% in the investigational arm and 8.9% in the control arm.

• Quality-of-life scores did not differ significantly between groups.

Pathologic Response ≠ Survival?

One of the most interesting findings was that achieving pCR did not predict survival outcomes. Some patients without pCR also survived long term. This suggests that pCR may not be a sufficient biomarker, particularly in patients with a BRCA mutation.

Clinical and Scientific Interpretation

• Optimal olaparib timingmay provide a model not only for BRCA-mutated patients but also for other combinations containing PARP inhibitors.

• This strategy may also offer advantages in fertility preservation for younger patients, reduced long-term toxicity, and shorter treatment duration.

• Biomarkers beyond pCR, such as ctDNA monitoring during treatment, may also improve future patient selection.

Conclusion: Timing Is Everything

PARTNER showed that starting olaparib 48 hours after chemotherapy can substantially improve survival in women with BRCA1/2-mutated early-stage breast cancer. This highlights the critical importance of timing chemotherapy and targeted agents.

This finding requires confirmation in larger studies but has the potential to change clinical practice.